Jundishapur Journal of Chronic Disease Care

Published by: Kowsar

Thyroid Cancer in Isfahan Province, Iran; Prevalence and Demographic Characteristics

Zahra Tolou Ghamari 1 , *
Author Information
1 Isfahan Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Article information
  • Jundishapur Journal of Chronic Disease Care: 8 (1); e86864
  • Published Online: January 13, 2019
  • Article Type: Research Article
  • Received: November 28, 2018
  • Revised: December 26, 2018
  • Accepted: December 29, 2018
  • DOI: 10.5812/jjcdc.86864

To Cite: Tolou Ghamari Z. Thyroid Cancer in Isfahan Province, Iran; Prevalence and Demographic Characteristics, Jundishapur J Chronic Dis Care. Online ahead of Print ; 8(1):e86864. doi: 10.5812/jjcdc.86864.

Copyright © 2019, Jundishapur Journal of Chronic Disease Care. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Shah JP. Thyroid carcinoma: Epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol. 2015;13(4 Suppl 4):3-6. [PubMed: 26430868]. [PubMed Central: PMC5526593].
  • 2. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol. 2002;161(5):1549-56. doi: 10.1016/S0002-9440(10)64433-1. [PubMed: 12414503]. [PubMed Central: PMC1850764].
  • 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 10.3322/caac.21442. [PubMed: 29313949].
  • 4. Safavi A, Azizi F, Jafari R, Chaibakhsh S, Safavi AA. Thyroid cancer epidemiology in Iran: A time trend study. Asian Pac J Cancer Prev. 2016;17(1):407-12. [PubMed: 26838247].
  • 5. Heidari Z, Abdani M, Mansournia MA. Insulin resistance associated with differentiated thyroid carcinoma: Penalized conditional logistic regression analysis of a matched case-control study data. Int J Endocrinol Metab. 2018;16(1). e14545. doi: 10.5812/ijem.14545. [PubMed: 29696038]. [PubMed Central: PMC5903382].
  • 6. Davies L, Morris LG, Haymart M, Chen AY, Goldenberg D, Morris J. American association of clinical endocrinologists and american college of endocrinology disease state clinical review: The increasing incidence of thyroid cancer. Endocr Pract. 2015;21(6):686-96. doi: 10.4158/EP14466.DSCR. [PubMed: 26135963]. [PubMed Central: PMC4923940].
  • 7. Radwan H, Hasan H, Ballout RA, Rizk R. The epidemiology of cancer in the United Arab Emirates: A systematic review. Medicine (Baltimore). 2018;97(50). e13618. doi: 10.1097/MD.0000000000013618. [PubMed: 30558043].
  • 8. Khader YS, Sharkas GF, Arkoub KH, Alfaqih MA, Nimri OF, Khader AM. The epidemiology and trend of cancer in Jordan, 2000-2013. J Cancer Epidemiol. 2018;2018:2937067. doi: 10.1155/2018/2937067. [PubMed: 30416523]. [PubMed Central: PMC6207872].
  • 9. Soheylizad M, Khazaei S, Jenabi E, Delpisheh A, Veisani Y. The relationship between human development index and its components with thyroid cancer incidence and mortality: Using the decomposition approach. Int J Endocrinol Metab. 2018;16(4). e65078. doi: 10.5812/ijem.65078. [PubMed: 30464773]. [PubMed Central: PMC6218660].
  • 10. Modirian M, Cheraghi Z, Rahimzadeh S, Moghaddam SS, Jarrahi AM. Burden assessment of thyroid cancer in Iran from 1990 to 2010: Lessons obtained from global burden of disease report 2010. Asian Pac J Cancer Prev. 2015;16(17):7743-8. [PubMed: 26625791].
  • 11. Mazdak H, Tolou-Ghamari Z. Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran. Arab J Urol. 2018;16(2):206-10. doi: 10.1016/j.aju.2017.11.017. [PubMed: 29892483]. [PubMed Central: PMC5992262].
  • 12. Ghamari ZT. Prevalence of stomach cancer in Isfahan province, Iran. Gulf J Oncolog. 2018;1(28):42-5. [PubMed: 30344133].
  • 13. Tolou Ghamari Z. Prevalence of lung cancer in Isfahan province, Iran. J Egypt Natl Canc Inst. 2018;30(2):57-9. doi: 10.1016/j.jnci.2018.03.001. [PubMed: 29691096].
  • 14. Tolou-Ghamari Z. Prevalence of skin cancer in Isfahan province, Iran. Jentashapir J Health Res. 2018;9(2). doi: 10.5812/jjhr.82743.
  • 15. Tolou-Ghamari Z. Prevalence of breast cancer in isfahan province, Iran. Women Health Bull. 2018;5(4). e82678. doi: 10.5812/whb.82678.
  • 16. Ghamari ZT, Tadayon F, Mazdak H. Prevalence of liver cancer in Isfahan province, Iran. Indonesian J Cancer. 2018;12(2):56-9.
  • 17. Sokouti M, Montazeri V, Fakhrjou A, Samankan S, Goldust M. Thyroid cancer, clinical and hystopathological study on patients under 25 years in Tabriz, Iran (2000-2012). Pak J Biol Sci. 2013;16(24):2003-8. [PubMed: 24517019].
  • 18. Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi AR, Tavangar SM, Malekzadeh R, et al. Endocrine cancer in Iran: Based on cancer registry system. Indian J Cancer. 2006;43(2):80-5. [PubMed: 16790945].
  • 19. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771-9. doi: 10.2217/fon.10.127. [PubMed: 21142662]. [PubMed Central: PMC3077966].
  • 20. Ahmadi A, Salehi F. Evaluation of observed and the expected incidence of common cancers: An experience from Southwestern of Iran, 2010-2014. J Res Med Sci. 2018;23:4. doi: 10.4103/jrms.JRMS_788_17. [PubMed: 29456561]. [PubMed Central: PMC5813294].
  • 21. Jafary F, Aminorroaya A, Amini M, Adibi A, Sirous M, Roohi E, et al. Thyroid incidentaloma in Isfahan, Iran - a population-based study. Endokrynol Pol. 2008;59(4):316-20. [PubMed: 18777502].
  • 22. Deandrea M, Gallone G, Veglio M, Balsamo A, Grassi A, Sapelli S, et al. Thyroid cancer histotype changes as observed in a major general hospital in a 21-year period. J Endocrinol Invest. 1997;20(2):52-8. [PubMed: 9125483].
  • 23. Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: The influence of access to care. Thyroid. 2013;23(7):885-91. doi: 10.1089/thy.2013.0045. [PubMed: 23517343]. [PubMed Central: PMC3704124].
  • 24. Tolou-Ghamari Z, Habibabadi JM, Palizban AA. Evidence-based pharmacotherapy of epilepsy. Arch Neurosci. 2015;2(1):6. doi: 10.5812/archneurosci.18468.
  • 25. Tolou-Ghamari Z, Mortazavi M, Palizban AA, Najafi MR. The investigation of correlation between Iminoral concentration and neurotoxic levels after kidney transplantation. Adv Biomed Res. 2015;4:59. doi: 10.4103/2277-9175.151876. [PubMed: 25802828]. [PubMed Central: PMC4361960].
  • 26. Tolou-Ghamari Z, Palizban AA. Laboratory monitoring of cyclosporine pre-dose concentration (C0) after kidney transplantation in Isfahan. Iran J Med Sci. 2003;28(2):81-5.
  • 27. Bushnik T, Evans WK. Sociodemographic characteristics associated with thyroid cancer risk in Canada. Health Rep. 2018;29(10):3-11. [PubMed: 30329144].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments